India Grants Patent for Gilead’s Hepatitis C Drug

US pharmaceutical giant Gilead has obtained a patent for its Hepatitis C drug from India. This patent could potentially stop affordable copies reaching millions of people in other countries.

The drug, Sovaldi, which costs $1,000 a pill in the United States, was rejected for a patent in January 2015 following opposition by health activists who said the science was not sufficiently new.

Patent Row No Hurdle for Gilead Pharma's India Plans
US drug maker Gilead Pharma says that the recent decision by the patent office, which rejected patent for one of its molecules, does not impact its India plans.

‘US-based drug maker Gilead has been granted a patent for its Hepatitis C drug 'Sovaldi' by India.’

Tweet it Now

But after an appeal by Gilead, the Indian Patent Office granted its application for the drug, chemically known as sofosbuvir, saying it found the "compounds novel, inventive and patentable".

"This decision underlines the scientific innovation involved in the development of this breakthrough treatment for chronic Hepatitis C," Gilead spokesman Nick Francis said in a statement.

The ruling will not immediately affect patients in India, where several firms are licensed by Gilead to produce low-cost versions of sofosbuvir for sale in developing countries.

UnitedHealth Suggests Gilead's Harvoni as Preferred Hepatitis C Treatment
UnitedHealth Group Inc, the largest U.S. health insurer, has mentioned Gilead Sciences Inc's Harvoni as the preferred hepatitis C treatment on its 2015 commercial drug coverage list.

But drug access campaigners slammed the decision, saying it could prevent the export of raw materials to other countries seeking to make the drug that some have hailed as a miracle cure.

"We know there are millions of people in other countries who now won't have affordable access because of this decision," said Leena Menghaney, South Asia head of the Medecins Sans Frontieres' Access Campaign.

Drug for Hepatitis C to be Launched in India by Gilead Sciences
The pill could treat six genotypes of hepatitis C if approved by regulators and is a combination of sofosbuvir and GS-5816.

"It will block a sustainable supply of key raw materials needed to produce the drug in countries like Egypt, Bangladesh and Pakistan, and hence affect production by new suppliers," she said.

Tahir Amin, co-founder of the group Intellectual Property, Initiative for Medicines, Access & Knowledge said the patent office's decision was "flawed".

Gilead Sciences to Allow 5 Indian Firms to Sell Hepatitis Generics in 90 Countries
Five Indian Generic Pharmaceutical Companies will sign licensing deals with Gilead Sciences Inc. to sell a low-cost version of its new hepatitis C medicines in 90 countries.

"(It) ignores the scientific facts and fails to uphold the standards of Indian patent law to ensure only new inventions are patented," he said.

India earned a nickname as the pharmacy to the developing world for its tough stance on patents, taking a view that they should be granted only for major innovations, not updates to existing compounds.

More than 130 million people live with chronic Hepatitis C worldwide, according to the World Health Organization, and 500,000 die each year from related liver diseases.

Source-AFP